Herpes Zoster (Shingles)
Basics
Description
- Results from reactivation of latent varicella-zoster virus (VZV) (human herpesvirus type 3) infection
- Postherpetic neuralgia (PHN) is defined as pain persisting at least 1 month after rash has healed. The term zoster-associated pain is more clinically useful.
- Herpes zoster ophthalmicus (HZO) is an important complication involving branch of the trigeminal nerve.
- Zoster usually presents as a painful unilateral vesicular eruption with a dermatomal distribution.
- System(s) affected: nervous; integumentary; exocrine
- Synonym(s): shingles
Epidemiology
Incidence
- Incidence increases with age—2/3 of cases occur in adults aged ≥50 years. Incidence is increasing overall as the U.S. population ages.
- Herpes zoster: 4/1,000 person-years
- PHN: 18% in adult patients with herpes zoster; 33% in patients ≥79 years of age
- Individual lifetime risk of 30% in the United States
Prevalence
~1 million new cases of herpes zoster annually in the United States
Pregnancy Considerations
May occur during pregnancy
Geriatric Considerations
- Increased incidence of zoster outbreaks
- Increased incidence of PHN
Pediatric Considerations
- Occurs less frequently in children
- Has been reported in newborns infected in utero
Etiology and Pathophysiology
Reactivation of VZV from dorsal root/cranial nerve ganglia; on reactivation, the virus replicates within neuronal cell bodies, and virions are carried along axons to dermatomal skin zones, causing local inflammation and vesicle formation.
Risk Factors
- Increasing age
- Immunosuppression (malignancy or chemotherapy)
- Physical trauma
- Female
- HIV infection
- Spinal surgery
General Prevention
- Shingrix recombinant herpes zoster vaccination is the preferred vaccine. It is recommended for adults who previously received Zostavax.
- Patients with active zoster may transmit disease-causing varicella virus—typically through direct contact.
Commonly Associated Conditions
Immunocompromised states, HIV infection, posttransplantation, immunosuppressive drugs, and malignancy
There's more to see -- the rest of this topic is available only to subscribers.